Marinomed Biotech AG Announces Strategic Partnership and Worldwide Licensing for Marinosolv® Technology in Inhalation Therapy

• Marinomed signs term sheet with Phargentis SA for a worldwide exclusive license of the Marinosolv® technology platform for an inhalation formulation.
• Partnership includes fee-for-service development, long-term milestone payments, and future royalties on product sales.
• The collaboration leverages Marinomed’s expertise to enhance solubility and bioavailability of a specialized respiratory therapeutic.

Korneuburg, Austria, May 19^th, 2026 – Marinomed Biotech AG (VSE:MARI), a dynamic biopharmaceutical company, today announced the signing of a term sheet with Phargentis SA. The term sheet contains the worldwide licensing of the proprietary Marinosolv® technology platform for the development of a high-performance formulation with a combination of different active pharmaceutical ingredients specifically designated for inhalation.

Under the terms of the agreement, Marinomed will provide specialized formulation services and technical expertise to develop a respiratory therapeutic utilizing the Marinosolv® platform. This technology is designed to significantly increase the solubility and bioavailability of hydrophobic compounds, enabling more effective delivery to the lungs and potentially reducing the required dosage for patients.

The financial structure of the partnership includes immediate fee-for-service components for the initial development phases. Furthermore, Marinomed is eligible to receive milestone payments tied to specific technical and clinical achievements throughout the development lifecycle, spanning several years. Upon successful commercialization, the agreement also stipulates the payment of royalties on net sales of the resulting product.

"This agreement marks another significant milestone in our strategy to monetize the Marinosolv® platform beyond our own internal pipeline," said Andreas Grassauer, CEO of Marinomed. "By applying our technology to inhalation therapies, we are addressing a critical need for better delivery of poorly soluble drugs in respiratory medicine. This partnership not only validates the versatility of our patent portfolio but also provides a sustainable revenue stream through services, milestones, and future royalties."

The Marinosolv® technology has already demonstrated its capability in various ophthalmic and nasal applications. This latest expansion into inhalation underscores the platform’s potential to revolutionize treatment paradigms across multiple therapeutic areas where drug solubility remains a barrier to clinical success.

About Marinosolv®

Marinosolv® is Marinomed’s proprietary technology platform designed to increase the solubility of hardly soluble compounds. This enables the development of aqueous formulations for sensitive tissues such as the eyes, nose, and lungs without the need for harsh solvents or preservatives, thereby improving both efficacy and local tolerability.

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.

About Phargentis SA

Phargentis, founded in 2015 and headquartered in Lugano Switzerland, develops Generic and innovative Super Generic products for the respiratory market with a strong focus on COPD and Asthma. Phargentis is an agile company that leverages robust global partnerships to execute a unique Early Market Entry strategy for Generics and global out-licensing for its diverse, competitive portfolio. Phargentis is co-owned by Chemholding (Switzerland), Helm Swiss (Switzerland) and Pharmaxis (Dubai). Its flagship product is generic Tiotropium bromide DPI, the fully interchangeable generic version of the world’s first-line COPD treatment, achieved European sales and is being planned to launch in other key markets.

For further inquiries contact:

Disclaimer

The new shares and subscription rights have not been and will not be registered under foreign securities laws – in particular under the U.S. Securities Act of 1933, as amended ("Securities Act") – with foreign securities authorities and may not be offered or sold, in particular in the United States of America ("US"), without registration or an exemption from the registration requirements under the Securities Act. This communication is not intended for distribution to or within the US and may not be distributed or forwarded to publications with general circulation in the US. This communication constitutes neither an offer to sell nor an invitation to subscribe for or purchase securities in any jurisdiction in which such an offer or such an invitation would be unlawful.